Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Kither Biotech, an Italy-based drug development spinout of University of Turin focused on pulmonary disease, has obtained €5.6m ($6.3m) in a series A round featuring Invitalia Ventures, Ersel Wealth Management, Club degli Investitori, Ace Venture, Elysia Capital, the Moschini family office and a number of private investors, including individuals from Italian Angels for Growth. The company is working on lung disease drugs led by a preclinical program indicated for cystic fibrosis, which will receive a share of the series A…
